Skip to main content

Table 4 Distribution of study horses by the AAEP grade for lameness at walk (LAMEW) on study days 0, 1, 3, and 6 for the meloxicam and placebo treatment groups

From: Evaluation of the efficacy of meloxicam for post-operative management of pain and inflammation in horses after orthopaedic surgery in a placebo controlled clinical field trial

Lameness at Walk

Meloxicam

Placebo

Day

Grade

N

%

N

%

Day 0

None (0)

22

71.0

21

72.4

Minimal (1)

1

3.2

4

13.8

Mild (2)

8

25.8

4

13.8

Moderate to severe (3–5)1

0

0.0

0

0.0

Day 1

None (0)

20

64.5

16

55.2

Minimal (1)

2

6.5

6

20.7

Mild (2)

9

29.0

7

24.1

Moderate to severe (3–5)1

0

0.0

0

0.0

Day 3

None (0)

22

71.0

19

65.5

Minimal (1)

7

22.6

6

20.7

Mild (2)

2

6.5

3

10.3

Moderate to severe (3–5)1

0

0.0

1

3.4

Day 6

None (0)

29

93.5

23

79.3

 

Minimal (1)

2

6.5

4

13.8

 

Mild (2)

0

0.0

2

6.9

 

Moderate to severe (3–5)1

0

0.0

0

0.0

 

Total

31

100.0

29

100.0

  1. 1Since all but one horse had LAMEW grades lower than 3, the grades 3–5 were combined.